Oxford Biomedica plc (LON:OXB)
London · Delayed Price · Currency is GBP · Price in GBX 502.00
+12.00 (2.45%)
Sep 25, 2026, 3:06 PM GMT
Oxford Biomedica Income Statement
Financials in millions GBP. Fiscal year is January - December.
Millions GBP. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 175.36 | 168.74 | 128.8 | 89.54 | 139.99 | 142.8 | |
Revenue Growth | 15.97% | 31.01% | 43.84% | -36.04% | -1.97% | 62.77% |
Cost of Revenue | 111.9 | 102.76 | 75.78 | 49.81 | 70.81 | 60.16 |
Gross Profit | 63.46 | 65.98 | 53.02 | 39.73 | 69.18 | 82.64 |
Selling, General & Admin | 88 | 93.16 | 92.84 | 116.97 | 23.12 | 13.95 |
Research & Development | 5.37 | 5.06 | 4.54 | 11.47 | 94.82 | 47.42 |
Other Operating Expenses | -0.94 | -1.14 | -3.53 | -2.8 | -2.31 | -0.87 |
Operating Expenses | 92.43 | 97.08 | 93.85 | 125.64 | 115.64 | 60.51 |
Operating Income | -28.97 | -31.1 | -40.83 | -85.91 | -46.46 | 22.13 |
Interest Expense | -14.99 | -13.86 | -9.84 | -10.67 | -8.69 | -0.86 |
Interest & Investment Income | 3.13 | 2.38 | 3.24 | 4.91 | 0.97 | - |
Currency Exchange Gain (Loss) | -1.36 | 2.81 | -0.62 | 1.94 | -7.98 | - |
Other Non Operating Income (Expenses) | -0.93 | -0.77 | -0.67 | -0.53 | -0.07 | -0.03 |
EBT Excluding Unusual Items | -43.1 | -40.55 | -48.72 | -90.26 | -62.21 | 21.25 |
Merger & Restructuring Charges | -1.3 | -1.3 | -0.2 | - | -5.1 | -1.2 |
Gain (Loss) on Sale of Assets | - | - | -0.07 | 1.02 | 21.39 | - |
Asset Writedown | -7.64 | - | - | -99.28 | -0.05 | -0.17 |
Other Unusual Items | 9.92 | 9.92 | 1.72 | - | - | - |
Pretax Income | -42.12 | -31.94 | -47.27 | -188.53 | -45.98 | 19.88 |
Income Tax Expense | -1.39 | -1.29 | 1.34 | -4.37 | -0.82 | 0.87 |
Earnings From Continuing Operations | -40.73 | -30.65 | -48.61 | -184.16 | -45.16 | 19.01 |
Minority Interest in Earnings | - | 0.52 | 5.42 | 26.67 | 6 | - |
Net Income | -40.73 | -30.13 | -43.19 | -157.49 | -39.16 | 19.01 |
Net Income to Common | -40.73 | -30.13 | -43.19 | -157.49 | -39.16 | 19.01 |
Net Income Growth | - | - | - | - | - | - |
Shares Outstanding (Basic) | 120 | 112 | 103 | 97 | 95 | 83 |
Shares Outstanding (Diluted) | 120 | 112 | 103 | 97 | 95 | 86 |
Shares Change | 15.25% | 8.18% | 7.15% | 1.82% | 10.76% | 7.10% |
EPS (Basic) | -0.34 | -0.27 | -0.42 | -1.63 | -0.41 | 0.23 |
EPS (Diluted) | -0.34 | -0.27 | -0.42 | -1.63 | -0.41 | 0.22 |
EPS Growth | - | - | - | - | - | - |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Free Cash Flow | -30.71 | -4.25 | -58.16 | -38.35 | -28.91 | 15.99 |
Free Cash Flow Per Share | -0.26 | -0.04 | -0.56 | -0.40 | -0.30 | 0.19 |
Gross Margin | 36.19% | 39.10% | 41.17% | 44.37% | 49.42% | 57.87% |
Operating Margin | -16.52% | -18.43% | -31.70% | -95.95% | -33.19% | 15.50% |
Profit Margin | -23.23% | -17.85% | -33.53% | -175.89% | -27.97% | 13.31% |
Free Cash Flow Margin | -17.51% | -2.52% | -45.16% | -42.83% | -20.65% | 11.20% |
EBITDA | -22.72 | -18.26 | -23.91 | -70.01 | -31.1 | 32.66 |
EBITDA Margin | -12.96% | -10.82% | -18.56% | -78.19% | -22.22% | 22.87% |
D&A For EBITDA | 6.24 | 12.84 | 16.92 | 15.9 | 15.36 | 10.53 |
EBIT | -28.97 | -31.1 | -40.83 | -85.91 | -46.46 | 22.13 |
EBIT Margin | -16.52% | -18.43% | -31.70% | -95.95% | -33.19% | 15.50% |
Effective Tax Rate | - | - | - | - | - | 4.37% |